Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
Environ Microbiol ; 15(12): 3210-7, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23782448

ABSTRACT

The Escherichia coli division protein FtsQ, which plays a central role in the septosome assembly, interacts with several protein partners of the division machinery. Its interaction with FtsB and FtsL allows the formation of the trimeric complex connecting the early cytoplasmic cell division proteins with the late, essentially periplasmic, ones. Little is known about the interactions that FtsQ contracts with other divisome components, besides the fact that all are localized in its periplasmic domain. In this domain, two independent subdomains, both involved in FtsQ, FtsI and FtsN interactions, were also identified. The study of FtsQ interaction-defective mutants constituted a basis to investigate the biological significance of its interactions. However, in the case of interactions where two independent sites are involved, mutation(s) in one domain can be suppressed by the presence of the still-functional second interaction region. To ascertain the biological role of these interactions, it is therefore necessary to select double mutants, where both sites are impaired. This paper describes the behaviour of FtsQ double mutants that have lost the ability to interact with FtsN, which is the last component in the hierarchy of divisome assembly, and is necessary to guarantee its stability and function.


Subject(s)
Cell Division , Escherichia coli Proteins/metabolism , Escherichia coli/cytology , Escherichia coli/metabolism , Membrane Proteins/metabolism , Escherichia coli/genetics , Escherichia coli Proteins/chemistry , Escherichia coli Proteins/genetics , Membrane Proteins/chemistry , Membrane Proteins/genetics , Mutation , Periplasm/metabolism , Protein Interaction Domains and Motifs
2.
Eur Respir J ; 37(6): 1352-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21109557

ABSTRACT

Increased tumour necrosis factor-α levels have been observed in bronchial biopsies and induced sputum from subjects with severe asthma. We investigated etanercept (ETN) as a therapeutic option for treating moderate-to-severe persistent asthma. In this 12-week, randomised, double-blind, placebo-controlled, phase 2 trial, subjects (n=132) with moderate-to-severe persistent asthma received subcutaneous injections of 25 mg ETN or placebo twice weekly, and were evaluated at baseline, and at weeks 2, 4, 8 and 12. The primary end-point was the change from baseline to week 12 in pre-bronchodilator forced expiratory volume in 1 s (FEV1)% predicted. Secondary end-points included morning peak expiratory flow, FEV1% pred, Asthma Control Questionnaire (5-item version), asthma exacerbations, provocative concentration of methacholine causing a 20% decrease in FEV1, and the Asthma Quality of Life Questionnaire. No significant differences were observed between ETN and placebo for any of the efficacy end-points. ETN treatment was well tolerated, with no unexpected safety findings observed during the study. Clinical efficacy of ETN was not shown in subjects with moderate-to-severe persistent asthma over 12 weeks. However, ETN treatment was a well-tolerated therapy. Studies in specific subsets of patients with asthma with longer-term follow-up may be needed to fully evaluate the clinical efficacy of ETN in this population.


Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Immunoglobulin G/therapeutic use , Receptors, Tumor Necrosis Factor/therapeutic use , Adolescent , Adult , Aged , Disease Progression , Etanercept , Female , Forced Expiratory Volume/drug effects , Humans , Male , Methacholine Chloride , Middle Aged , Quality of Life , Severity of Illness Index , Surveys and Questionnaires , Young Adult
3.
N Biotechnol ; 27(6): 870-81, 2010 Dec 31.
Article in English | MEDLINE | ID: mdl-20460179

ABSTRACT

FtsQ is a highly conserved component of the divisome that plays a central role in the assembly of early and late cell division proteins. The biological activity of this protein is still largely unknown, but its ability to interact with many components of the divisome was described by both two-hybrid assays and co-immunoprecipitation experiments. This paper describes the behaviour of ftsQ point mutants, created by random mutagenesis without regard to their phenotype, in which FtsQ is impaired in its ability to interact with its Escherichia coli division partners. Our results allow the identification of FtsQ residues involved in the interaction with other partner proteins and the determination of the biological significance of these interactions. The knowledge derived by this study could constitute not only the basis for understanding how these proteins assemble in the divisome, but also a starting point for the design of new antibacterial drugs that disrupt the bacterial division machinery.


Subject(s)
Anti-Bacterial Agents/pharmacology , Escherichia coli Proteins/genetics , Escherichia coli Proteins/metabolism , Escherichia coli/drug effects , Escherichia coli/metabolism , Membrane Proteins/genetics , Membrane Proteins/metabolism , Point Mutation , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Escherichia coli/cytology , Escherichia coli/genetics , Genetic Complementation Test , Humans
4.
Res Microbiol ; 161(2): 118-26, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20079830

ABSTRACT

A method which enables selection of protein mutants impaired in their ability to interact with their normal protein partners is presented here. The method is the two-phage two-hybrid assay adapted for mutant selection. In the two-phage assay, the interaction between two proteins enables the formation of a functional hybrid lambdoid repressor that shuts down expression of a reporter gene governed by a chimeric promoter/operator region. To adapt the assay to interaction mutant selection, antibiotic resistance was used as a reporter gene. In this case, the interaction between the two proteins resulted in antibiotic sensitivity, whereas the loss of interaction conferred resistance to the bacterial strain. Therefore, turning on reporter gene expression highlights the loss of interaction due to a mutation in one of the genes for the two protein partners, and leads to direct selection of the mutants regardless of the mutant phenotype. In this paper, application of this method to isolation of interaction mutants in proteins involved in Escherichia coli K12 cytokinesis is reported.


Subject(s)
Escherichia coli K12/genetics , Escherichia coli K12/metabolism , Escherichia coli Proteins/metabolism , Mutant Proteins/metabolism , Protein Interaction Mapping , Two-Hybrid System Techniques , Bacteriophages/genetics , Chimera , Drug Resistance, Bacterial , Escherichia coli Proteins/genetics , Genes, Reporter , Mutant Proteins/genetics , Protein Binding , Selection, Genetic
5.
Br J Dermatol ; 159(5): 1177-85, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18673365

ABSTRACT

BACKGROUND: In previous studies, etanercept 25 mg twice weekly (BIW) or 50 mg BIW significantly reduced disease severity in patients with plaque psoriasis and demonstrated a favourable safety profile. OBJECTIVES: To assess the efficacy and safety of etanercept 50 mg administered once weekly (QW) compared with placebo in patients with moderate-to-severe plaque psoriasis over 24 weeks. METHODS: This study was conducted in two parts: (i) a 12-week, double-blind, placebo-controlled phase, in which patients received etanercept 50 mg QW or placebo QW; and (ii) a 12-week, open-label extension phase, in which all patients received etanercept 50 mg QW. Primary endpoint was a 75% or greater improvement from baseline in the Psoriasis Area and Severity Index (PASI 75) at week 12. Secondary endpoints included percentage PASI improvement and Physician's Global Assessment (PGA). RESULTS: One hundred and forty-two patients were analysed in the double-blind phase; 126 patients entered the open-label phase. At week 12, significantly more patients receiving etanercept 50 mg QW (37.5%) achieved PASI 75 response than patients receiving placebo (2.2%; P < 0.0001). At week 24, 71.1% in the etanercept-etanercept group and 44.4% in the placebo-etanercept group achieved PASI 75. Mean percentage of PASI improvement from baseline was 55.4% with etanercept vs. 9.4% worsening with placebo at week 12 (P < 0.0001), with 77.4% and 57.7% improvement in the etanercept-etanercept and placebo-etanercept groups at week 24. A PGA score of 0-1 (clear-almost clear) was achieved by 64% and 42% in the etanercept-etanercept and placebo-etanercept groups at week 24, respectively. Etanercept 50 mg QW was well tolerated. No deaths, serious infections, opportunistic infections (including tuberculosis), demyelinating disorders, malignancies or new safety signals were reported. CONCLUSIONS: Nearly three-quarters of patients with moderate-to-severe psoriasis receiving etanercept 50 mg QW achieved significant improvement in disease severity over 24 weeks. This study also showed a favourable tolerability and safety profile with etanercept 50 mg QW.


Subject(s)
Immunoglobulin G/administration & dosage , Immunosuppressive Agents/administration & dosage , Psoriasis/drug therapy , Receptors, Tumor Necrosis Factor/administration & dosage , Adult , Double-Blind Method , Drug Administration Schedule , Etanercept , Female , Humans , Injections, Subcutaneous , Male , Middle Aged , Treatment Outcome
6.
Microbiology (Reading) ; 153(Pt 1): 124-38, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17185541

ABSTRACT

FtsQ, an essential protein for the Escherichia coli divisome assembly, is able to interact with various division proteins, namely FtsI, FtsL, FtsN, FtsB and FtsW. In this paper, the FtsQ domains involved in these interactions were identified by two-hybrid assays and co-immunoprecipitations. Progressive deletions of the ftsQ gene suggested that the FtsQ self-interaction and its interactions with the other proteins are localized in three periplasmic subdomains: (i) residues 50-135 constitute one of the sites involved in FtsQ, FtsI and FtsN interaction, and this site is also responsible for FtsW interaction; (ii) the FtsB interaction is localized between residues 136 and 202; and (iii) the FtsL interaction is localized at the very C-terminal extremity. In this third region, the interaction site for FtsK and also the second site for FtsQ, FtsI, FtsN interactions are located. As far as FtsW is concerned, this protein interacts with the fragment of the FtsQ periplasmic domain that spans residues 67-75. In addition, two protein subdomains, one constituted by residues 1-135 and the other from 136 to the end, are both able to complement an ftsQ null mutant. Finally, the unexpected finding that an E. coli ftsQ null mutant can be complemented, at least transiently, by the Streptococcus pneumoniae divIB/ftsQ gene product suggests a new strategy for investigating the biological significance of protein-protein interactions.


Subject(s)
Escherichia coli Proteins/metabolism , Escherichia coli/physiology , Membrane Proteins/metabolism , Bacterial Proteins/genetics , Cell Cycle Proteins/genetics , Cell Division , Escherichia coli Proteins/chemistry , Escherichia coli Proteins/genetics , Genetic Complementation Test , Membrane Proteins/chemistry , Membrane Proteins/genetics , Periplasm/metabolism , Protein Binding/physiology , Protein Structure, Tertiary/physiology , Streptococcus pneumoniae/chemistry , Streptococcus pneumoniae/genetics
7.
Ann Rheum Dis ; 65(12): 1572-7, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16968715

ABSTRACT

OBJECTIVE: To compare the efficacy, pharmacokinetics and safety of etanercept 50 mg once weekly with 25 mg twice weekly and placebo in patients with ankylosing spondylitis. METHODS: A 12-week, double-blind, placebo-controlled study compared the effects of etanercept 50 mg once weekly, etanercept 25 mg twice weekly and placebo in 356 patients with active ankylosing spondylitis (3:3:1 randomisation, respectively). The primary end point was the proportion of patients achieving a response at week 12 based on the Assessment in Ankylosing Spondylitis Working Group criteria (ASAS 20). The pharmacokinetics of etanercept 50 mg once weekly and 25 mg twice weekly were analysed. RESULTS: Baseline characteristics and disease activity were similar among the three groups: etanercept 50 mg once weekly, etanercept 25 mg twice weekly and placebo. The percentage of patients discontinuing therapy was 9.0%, 9.3% and 13.7% for the three respective groups. ASAS 20 response at 12 weeks was achieved by 74.2% of patients with etanercept 50 mg once weekly and 71.3% of those with etanercept 25 mg twice weekly, both significantly higher than the percentage of patients taking placebo (37.3%, p<0.001). Percentages of patients with ASAS 5/6 response (70.3%, 72.0% and 27.5%, respectively; p<0.001) and those with ASAS 40 response (58.1%, 53.3% and 21.6%, respectively; p<0.001) followed a similar pattern. Significant improvement (p<0.05) was seen in measures of disease activity, back pain, morning stiffness and C reactive protein levels as early as 2 weeks. Serum etanercept exposure was similar between the etanercept groups. Incidence of treatment-emergent adverse events, including infections, was similar among all three groups, and no unexpected safety issues were identified. CONCLUSIONS: Patients with ankylosing spondylitis can expect a comparable significant improvement in clinical outcomes with similar safety when treated with etanercept 50 mg once weekly or with 25 mg twice weekly.


Subject(s)
Antirheumatic Agents/administration & dosage , Immunoglobulin G/administration & dosage , Receptors, Tumor Necrosis Factor/administration & dosage , Spondylitis, Ankylosing/drug therapy , Adult , Antirheumatic Agents/adverse effects , Antirheumatic Agents/blood , Double-Blind Method , Drug Administration Schedule , Etanercept , Female , Humans , Immunoglobulin G/adverse effects , Immunoglobulin G/blood , Male , Middle Aged , Receptors, Tumor Necrosis Factor/blood , Severity of Illness Index , Spondylitis, Ankylosing/blood , Treatment Outcome
8.
Ann Rheum Dis ; 63(12): 1611-7, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15331394

ABSTRACT

OBJECTIVE: To evaluate long term efficacy of three iterative courses of three weekly intra-articular (IA) injections of NRD101 in the treatment of symptomatic knee osteoarthritis (OA). PATIENTS AND METHODS: A 1 year prospective, multicentre, randomised, double blind, placebo controlled study of 301 patients aged >50 years with painful and radiological medial knee OA. Patients were randomly assigned into three groups receiving: (1) three courses of three IA injections of hyaluronic acid (HA) + oral placebo; (2) IA injections of saline solution + diacerein 100 mg/day; (3) IA injections of saline solution + oral placebo. Demographic data and symptomatic criteria-pain, Lequesne's index, patient's global assessment of disease activity, percentage of painful days-were obtained during the study; primary structural criterion was JSW. Efficacy criteria were changes in pain VAS, joint space narrowing (JSN), and percentage of progressors (JSN >0.5 mm). An intention to treat analysis was used for symptomatic variables, and completer analysis for structural variables. RESULTS: Baseline characteristics were similar between the three groups. Mean (SD) improvement in pain VAS was clinically relevant (-33.9 (27.3), n = 301), but with no difference between the groups (p = 0.96). JSW deteriorated (-0.09 (0.55) mm, n = 277, p = 0.01), but with no difference between the groups (p = 0.82). Percentages of progressors were 17.7, 18.9, and 20.3% (p = 0.90), in groups 1, 2, and 3, respectively. CONCLUSION: A weak but statistically significant structural deterioration occurred over 1 year, together with clinically relevant symptomatic improvement in patients receiving oral drug and iterative IA injections. Symptomatic and/or structural effects for both this new HA compound and diacerein were not demonstrated.


Subject(s)
Anthraquinones/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Hyaluronic Acid/analogs & derivatives , Hyaluronic Acid/therapeutic use , Osteoarthritis, Knee/drug therapy , Aged , Anthraquinones/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Disease Progression , Double-Blind Method , Female , Humans , Hyaluronic Acid/adverse effects , Injections, Intra-Articular , Male , Middle Aged , Pain Measurement , Prospective Studies , Severity of Illness Index , Treatment Outcome
9.
Microbiology (Reading) ; 149(Pt 12): 3353-3359, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14663069

ABSTRACT

The ability of each of the nine Escherichia coli division proteins (FtsZ, FtsA, ZipA, FtsK, FtsQ, FtsL, FtsW, FtsI, FtsN) to interact with itself and with each of the remaining eight proteins was studied in 43 possible combinations of protein pairs by the two-hybrid system previously developed by the authors' group. Once the presumed interactions between the division proteins were determined, a model showing their temporal sequence of assembly was developed. This model agrees with that developed by other authors, based on the co-localization sequence in the septum of the division proteins fused with GFP. In addition, this paper shows that the authors' assay, which has already proved to be very versatile in the study of prokaryotic and eukaryotic protein interaction, is also a powerful instrument for an in vivo study of the interaction and assembly of proteins, as in the case of septum division formation.


Subject(s)
Escherichia coli Proteins/chemistry , Escherichia coli Proteins/metabolism , Bacterial Proteins/chemistry , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Base Sequence , Cell Division , DNA, Bacterial/genetics , Dimerization , Escherichia coli/genetics , Escherichia coli/growth & development , Escherichia coli/metabolism , Escherichia coli Proteins/genetics , Macromolecular Substances , Models, Biological , Mutation , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Two-Hybrid System Techniques
10.
Mol Genet Genomics ; 269(4): 517-25, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12768413

ABSTRACT

It has been proposed that transcription introduces a bias into the random process of mutation. Although this hypothesis is supported by experimental data for mutations arising during active bacterial growth, the role of transcription in mutagenesis in non-dividing bacteria is entirely hypothetical. In the present study, we tested the hypothesis of a possible role of transcription in a non-dividing E. coli K12 strain. In this strain (BD010), a mutated trpB allele (trpB9578), placed under stringent transcriptional control, was tested for the appearance of prototrophic revertants on synthetic medium lacking tryptophan. The number of phenotypic revertants which appeared in the absence of trp transcription was compared to that observed when the mutated gene was continuously transcribed. Our results showed that transcription of trpB is not mutagenic under conditions of tryptophan starvation, and that the frequency of TrpB+ reversion is solely a function of the duration of starvation.


Subject(s)
Escherichia coli/genetics , Mutation , Transcription, Genetic
11.
Microbiology (Reading) ; 147(Pt 6): 1651-1656, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11390696

ABSTRACT

The development of a convenient and promising alternative to the various two-hybrid methods that are used to study protein-protein interactions is described. In this system, a lambdoid chimeric operator is recognized by a hybrid repressor formed by two chimeric monomers whose C-terminal domains are composed of heterologous proteins (or protein domains). Only if these proteins efficiently dimerize in vivo is a functional repressor formed able to bind the chimeric operator and shut off the synthesis of a downstream reporter gene. This new approach was tested with several interacting proteins ranging in size from less than 100 to more than 800 amino acids and, to date, no size or topology limit has been detected.


Subject(s)
Escherichia coli/genetics , Operator Regions, Genetic , Recombinant Fusion Proteins/genetics , Bacteriophages/genetics , Dimerization , Escherichia coli/metabolism , Genes, Reporter , Protein Structure, Tertiary , Recombinant Fusion Proteins/metabolism , Repressor Proteins/metabolism , Reproducibility of Results , Two-Hybrid System Techniques , beta-Galactosidase/genetics , beta-Galactosidase/metabolism
12.
Microbiology (Reading) ; 146 ( Pt 3): 591-598, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10746762

ABSTRACT

Mutations induced by the integration of a Mugem2ts prophage can revert at frequencies around 1x10(-6). In these revertant clones, the prophage excised from its original localization is not lost but reintegrated elsewhere in the host genome. One of the most intriguing aspects of this process is that the prophage reintegration is not randomly distributed: there is a strong correlation between the original site of insertion (the donor site) and the target site of the phage DNA migration (the receptor site). In this paper, it is shown that in the excision-reintegration process mediated by Mugem2ts, the position of the initial prophage site strongly influences the location of the reintegration site. In addition, for each donor site, the receptor site is a discrete DNA region within which the excised Mu DNA can reintegrate and the two sites implicated in phage DNA migration must be located on the same DNA molecule. These data suggest the involvement of nucleoid folding in the excision-reintegration process.


Subject(s)
Bacteriophage mu/genetics , Bacteriophage mu/physiology , Escherichia coli/virology , Lysogeny , Virus Activation , Bacteriophage mu/metabolism , Base Sequence , DNA, Viral/genetics , DNA-Binding Proteins/metabolism , Molecular Sequence Data
13.
Microbiology (Reading) ; 145 ( Pt 6): 1485-1490, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10411275

ABSTRACT

A hybrid system which takes advantage of the properties of the lambda repressor allows detection of protein-protein interactions. Fusion of the cI N-terminal domain to a heterologous protein will result in a functional lambda repressor, able to strongly bind to its operator and conferring immunity to lambda infection only when the heterologous protein dimerizes efficiently. In this paper, construction of a recombinant plasmid which allows detection of the activity of the lambda chimeric repressor formed by the N-terminal part of cI fused with a heterologous protein is reported. This construct is interesting due to its potential to be integrated in any target gene of the bacterial host, thus permitting this hybrid assay to be performed, not only in Escherichia coli strains, but in every bacterial genus where the reporter gene can be expressed. In addition, because of its modular construction, this plasmid can be easily modified to be exploitable in many experimental situations, such as in the detection of promoter region activity.


Subject(s)
Bacteriophage lambda/genetics , DNA-Binding Proteins , Escherichia coli/genetics , Repressor Proteins/genetics , DNA, Recombinant , Dimerization , Genes, Reporter , Genetic Engineering/methods , Lac Operon , Plasmids/genetics , Viral Proteins , Viral Regulatory and Accessory Proteins
14.
Mol Microbiol ; 32(2): 265-74, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10231484

ABSTRACT

A hybrid assay, based on the properties of the lambda repressor, was developed to detect FtsZ dimerization in Escherichia coli in vivo. A gene fusion comprising the N-terminal end of the lambda cI repressor gene and the complete E. coli ftsZ gene was constructed. The fused protein resulted in a functional lambda repressor and was able to complement the thermosensitive mutant ftsZ84. Using the same strategy, a series of 10 novel mutants of FtsZ that are unable to dimerize was selected, and a deletion analysis of the protein was carried out. Characterization of these mutants allowed the identification of three separate FtsZ portions: the N-terminal of about 150 amino acids; the C-terminal of about 60 amino acids, which corresponds to the less conserved portion of the protein; and a central region of about 150 residues. Mutants belonging to this region would define the dimerization domain of FtsZ.


Subject(s)
Bacterial Proteins/chemistry , Bacterial Proteins/metabolism , Cytoskeletal Proteins , Escherichia coli/metabolism , Bacterial Proteins/genetics , Bacteriophage lambda/physiology , Blotting, Western , Dimerization , Escherichia coli/growth & development , Escherichia coli/virology , Gene Deletion , Mutation , Plasmids/genetics , Polymerase Chain Reaction/methods , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism , Recombination, Genetic
15.
Rev Rhum Engl Ed ; 66(2): 79-85, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10084166

ABSTRACT

OBJECTIVE: Several randomized trials have suggested recently that epidural steroid injections may not be a valid treatment in common low back pain and sciatica. To clarify this issue, we conducted a critical appraisal of relevant randomized trials published up to 1997. Attention was directed to methodological quality, results, and clinical implications. METHOD: A Medline search identified 13 trials published between 1966 and 1997. Trial methodology was evaluated using a 100-point grid based on four groups of items, namely study population, therapeutic intervention, evaluation method, and data presentation and analysis. RESULTS: Methodology quality scores ranged from 12 to 84 and were unrelated to the results of epidural steroid therapy. Five trials demonstrated greater pain relief within the first month in the steroid group as compared to the control group. Eight trials found no measurable benefits. Obstacles to meaningful comparisons across studies included differences in the patient populations, steroid used, volume injected, and number of injections. None of the published studies used the injection modalities that are standard practice in France. CONCLUSION: Whether epidural steroids are effective in common low back pain and sciatica cannot be determined based on our review.


Subject(s)
Glucocorticoids/administration & dosage , Low Back Pain/drug therapy , Randomized Controlled Trials as Topic , Sciatica/drug therapy , Evaluation Studies as Topic , Follow-Up Studies , Glucocorticoids/therapeutic use , Humans , Injections, Epidural , Low Back Pain/diagnosis , Pain Measurement , Retrospective Studies , Sciatica/diagnosis , Severity of Illness Index , Treatment Outcome
16.
Appl Environ Microbiol ; 64(10): 4053-6, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9758840

ABSTRACT

A method was developed for extraction of DNA from Chroococcidiopsis that overcomes obstacles posed by bacterial contamination and the presence of a thick envelope surrounding the cyanobacterial cells. The method is based on the resistance of Chroococcidiopsis to lysozyme and consists of a lysozyme treatment followed by osmotic shock that reduces the bacterial contamination by 3 orders of magnitude. Then DNase treatment is performed to eliminate DNA from the bacterial lysate. Lysis of Chroococcidiopsis cells is achieved by grinding with glass beads in the presence of hot phenol. Extracted DNA is further purified by cesium-chloride density gradient ultracentrifugation. This method permitted the first molecular approach to the study of Chroococcidiopsis, and a 570-bp fragment of the gene ftsZ was cloned and sequenced.

17.
Virology ; 241(1): 73-9, 1998 Feb 01.
Article in English | MEDLINE | ID: mdl-9454718

ABSTRACT

The gem operon of bacteriophage Mu, responsible for the complex phenomenon of phage conversion, is included in the so called "semiessential early" region of phage DNA. Unlike the other early genes of the phage which are transcribed from the pe promoter, expression of the gem operon is driven by its own promoter, which escapes the control of the repressor. In fact, the transcript corresponding to gem was detected in immune lysogens by using a combined reverse transcription and a subsequent amplification of the resulting cDNA. The transcription initiation site from pgem was determined by primer extension mapping experiments and localized at 8217 bp from the left end of phage DNA. Two elements which could perform the negative control of gem were also identified. The first is a phage product, GemB, which presumably interferes with gem expression at a posttranscriptional level, whereas the second is a structural element, an inverted repeat immediately downstream of pgem, which acts as a terminator for the transcripts starting from pe. These transcripts could regulate gem expression by interfering with the initiation of transcription from pgem.


Subject(s)
Bacteriophage mu/genetics , Gene Expression Regulation, Viral , Operon , Base Sequence , DNA, Viral , Molecular Sequence Data , Promoter Regions, Genetic , Repetitive Sequences, Nucleic Acid , Transcription, Genetic
18.
Ann Rheum Dis ; 57(10): 624-9, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9893575

ABSTRACT

OBJECTIVES: (1) To assess reproducibility of medial knee joint space width (JSW) measurement in healthy subjects and osteoarthritic (OA) patients. (2) To define minimal relevant radiological change in knee JSW based on the reproducibility of its measurement. PATIENTS AND METHODS: (1) Healthy volunteers: in the first part of the study, 20 knees of healthy adult volunteers were radiographed in the weightbearing, anteroposterior extended view, twice, two weeks apart, using three different radiographic procedures: (a) without guidelines, (b) with guidelines and without fluoroscopy, (c) with guidelines and fluoroscopy. (2) Knee OA patients: in the second part of the study, 36 knees of OA patients were radiographed twice with guidelines and without fluoroscopy. JSW was measured blindly using a graduated magnifying glass. Based on the Bland and Altman graphic approach, cut off points defining minimal relevant radiological change are proposed. RESULTS: Standard deviation (SD) of differences in JSW measurement between two sets of knee radiographs in healthy subjects were 0.66 mm for radiography performed without guidelines, 0.37 mm for radiography performed with guidelines and without fluoroscopy, and 0.31 mm for radiography with guidelines and fluoroscopy. SD of differences in JSW measurement in OA patients were 0.32 mm for radiography performed with guidelines and without fluoroscopy. A minimal relevant change in JSW between two radiographs performed in healthy subjects can be defined by a change of at least 1.29 or 0.59 mm when radiographs are taken without guidelines, and with guidelines and fluoroscopy, respectively. When radiographs are taken with guidelines and without fluoroscopy, the change must be at least 0.73 mm. A similar figure, 0.64 mm was observed in knee OA patients. CONCLUSION: Definition of radiological progression varies greatly according to the radiographic procedure chosen. Use of guidelines reduces the threshold of progression required to consider that change between two measures is relevant.


Subject(s)
Osteoarthritis, Knee/diagnostic imaging , Adult , Disease Progression , Fluoroscopy , Humans , Knee Joint/anatomy & histology , Knee Joint/diagnostic imaging , Male , Middle Aged , Osteoarthritis, Knee/pathology , Practice Guidelines as Topic , Reference Values , Reproducibility of Results
19.
FEMS Microbiol Lett ; 154(1): 59-64, 1997 Sep 01.
Article in English | MEDLINE | ID: mdl-9297821

ABSTRACT

Escherichia coli K12 strains lysogenic for Mu gem2ts with the prophage inserted in a target gene (i.e., lacZ::Mu gem2ts lysogenic strains) revert to Lac+ by prophage precise excision with a relatively high frequency (about 1 x 10(-6)). The revertants obtained are still lysogens with the prophage inserted elsewhere in the bacterial chromosome. We have observed that, with the time of storage in stabs, bacterial cultures lysogenic for Mu gem2ts lose the ability to excise the prophage. The mutation responsible for this effect was co-transducible with the gyrB gene. After the removal of the prophage by P1 vir transduction from these strains, one randomly chosen clone, R3538, was further analyzed. It shows an increment of DNA supercoiling of plasmid pAT153, used as a reporter, and a reduced beta-galactosidase activity. On the other hand, R3538 is totally permissive to both lytic and lysogenic cycles of bacteriophage Mu.


Subject(s)
Bacteriophage mu/physiology , Escherichia coli/genetics , Escherichia coli/virology , Virus Integration/physiology , Bacterial Proteins/genetics , Bacteriophage mu/growth & development , DNA, Bacterial/analysis , DNA, Superhelical/genetics , Gene Expression Regulation, Viral , Genes, Viral/genetics , Genome, Viral , Mutation/physiology , Operon/physiology
20.
Res Microbiol ; 148(7): 585-91, 1997.
Article in English | MEDLINE | ID: mdl-9765843

ABSTRACT

The gem2ts mutant of bacteriophage Mu induced synchrony of cell division on bacteria surviving infection. Induction of synchronous growth could also be observed as a response to the entire infected bacterial population, as in the case of infection of hic mutants, a peculiar class of gyrB alleles. After Mu wild-type or Mu gem2ts infection of hic mutants, there was a lack of viral DNA integration and replication, while phage gene expression (including that of A gene, coding for the transposase) seemed to be quite normal. These data indicate that the mechanism of bacterial synchronization induced by Mu gem2ts does not require integration nor replication of the phage DNA.


Subject(s)
Bacteriophage mu/genetics , Cell Cycle/physiology , DNA, Viral/genetics , Escherichia coli/growth & development , Lysogeny/physiology , Cell Division , DNA Replication , DNA, Bacterial/analysis , DNA, Viral/analysis , Escherichia coli/cytology , Escherichia coli/virology , Polymerase Chain Reaction , RNA, Bacterial/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...